OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SLNO59

Soleno Therapeutics Inc

Biotechnology & Medical ResearchVerified

Capital Structure and Liquidity Soleno Therapeutics Inc maintains a strong liquidity position, with a current ratio of 5.8, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $70.1 million, which is a substantial portion of its total assets of $563.8 million. The company's long-term debt is relatively low at $49.9 million, and its debt-to-equity ratio is 0.11, suggesting a conservative capital structure. The free cash flow of $22.8 million further supports the company's liquidity and financial flexibility. ### Profitability and Returns The company's profitability is reflected in its gross profit of $187.7 million and operating income of $9.4 million, with a net income of $20.9 million. The return on equity (ROE) is 4.64%, and the return on assets (ROA) is 3.71%, which are in line with the industry's preferred metrics for biotechnology firms. These returns suggest that the company is generating reasonable returns on its equity and assets, though there is room for improvement to outperform the industry median. ### Segments and Geographic Exposure Soleno Therapeutics Inc operates as a single business segment, focusing on the development and commercialization of pharmaceutical products. The company's revenue is primarily derived from the United States, with no significant international exposure disclosed in the available data. This concentration in a single geographic market may pose a risk if the U.S. market experiences regulatory or economic challenges. ### Growth Trajectory The company's revenue for the latest period is $190.4 million, and while there are no specific growth projections provided, the company's strong liquidity and positive cash flows suggest a stable financial position. The company's capital expenditure is minimal at -$73,000, indicating a low level of investment in physical assets, which is typical for a biotechnology firm that may focus more on R&D and product development. ### Risk Factors The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The ESG score of 20.50 and a grade of D+ suggest that the company has room for improvement in its environmental, social, and governance practices. The low environment pillar score of 0 and the governance pillar score of 24.17 highlight areas where the company could enhance its sustainability and corporate governance. ### Recent Events The company's recent financial performance is reflected in its last actual EPS of $0.39 and revenue of $190.4 million. There are no specific recent events or filings mentioned that would significantly impact the company's operations or financial position.

30-day price · SLNO+22.90 (+76.2%)
Low$29.43High$52.96Close$52.95As of10 May, 00:00 UTC
Profile
CompanySoleno Therapeutics Inc
TickerSLNO.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Soleno Therapeutics Inc is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the area of endocrinology and metabolic disorders.

Classification. Soleno Therapeutics Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

### Capital Structure and Liquidity Soleno Therapeutics Inc maintains a strong liquidity position, with a current ratio of 5.8, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $70.1 million, which is a substantial portion of its total assets of $563.8 million. The company's long-term debt is relatively low at $49.9 million, and its debt-to-equity ratio is 0.11, suggesting a conservative capital structure. The free cash flow of $22.8 million further supports the company's liquidity and financial flexibility. ### Profitability and Returns The company's profitability is reflected in its gross profit of $187.7 million and operating income of $9.4 million, with a net income of $20.9 million. The return on equity (ROE) is 4.64%, and the return on assets (ROA) is 3.71%, which are in line with the industry's preferred metrics for biotechnology firms. These returns suggest that the company is generating reasonable returns on its equity and assets, though there is room for improvement to outperform the industry median. ### Segments and Geographic Exposure Soleno Therapeutics Inc operates as a single business segment, focusing on the development and commercialization of pharmaceutical products. The company's revenue is primarily derived from the United States, with no significant international exposure disclosed in the available data. This concentration in a single geographic market may pose a risk if the U.S. market experiences regulatory or economic challenges. ### Growth Trajectory The company's revenue for the latest period is $190.4 million, and while there are no specific growth projections provided, the company's strong liquidity and positive cash flows suggest a stable financial position. The company's capital expenditure is minimal at -$73,000, indicating a low level of investment in physical assets, which is typical for a biotechnology firm that may focus more on R&D and product development. ### Risk Factors The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The ESG score of 20.50 and a grade of D+ suggest that the company has room for improvement in its environmental, social, and governance practices. The low environment pillar score of 0 and the governance pillar score of 24.17 highlight areas where the company could enhance its sustainability and corporate governance. ### Recent Events The company's recent financial performance is reflected in its last actual EPS of $0.39 and revenue of $190.4 million. There are no specific recent events or filings mentioned that would significantly impact the company's operations or financial position.
Key takeaways
  • Soleno Therapeutics Inc has a strong liquidity position with a current ratio of 5.8 and $70.1 million in cash and equivalents.
  • The company's conservative capital structure, with a debt-to-equity ratio of 0.11, supports financial stability.
  • The company's ROE of 4.64% and ROA of 3.71% indicate reasonable returns, though there is potential to outperform the industry median.
  • The company's operations are concentrated in the United States, which may pose a geographic risk.
  • The company's ESG score of 20.50 and a D+ grade suggest areas for improvement in sustainability and governance practices.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$190.4M
Gross profit$187.7M
Operating income$9.4M
Net income$20.9M
R&D
SG&A
D&A
SBC
Operating cash flow$46.8M
CapEx-$73.0k
Free cash flow$22.8M
Total assets$563.8M
Total liabilities$113.7M
Total equity$450.1M
Cash & equivalents$70.1M
Long-term debt$49.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$450.1M
Net cash$20.2M
Current ratio5.8
Debt/Equity0.1
ROA3.7%
ROE4.6%
Cash conversion2.2%
CapEx/Revenue-0.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricSLNOActivity
Op margin4.9%2.4% medp25 -91.8% · p75 12.5%above median
Net margin11.0%1.2% medp25 -98.4% · p75 10.4%top quartile
Gross margin98.6%45.6% medp25 29.8% · p75 66.7%top quartile
CapEx / revenue-0.0%-5.2% medp25 -15.8% · p75 -1.7%top quartile
Debt / equity11.0%9.3% medp25 0.1% · p75 43.8%above median
Observations
IR observations
Last actual EPS0.39 USD
Last actual revenue190,405,000 USD
market data ESG Score20.50 (0-100, higher is better)
Environment pillar0 (0-100)
Social pillar31.48 (0-100)
Governance pillar24.17 (0-100)
ESG controversies score0.70 (0-100, higher = fewer controversies)
ESG gradeD+
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 14:55 UTC#5b2a5b54
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 11:35 UTCJob: 5d9389d0